These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 7648770)

  • 1. Dipyrone metabolism in liver disease.
    Zylber-Katz E; Caraco Y; Granit L; Levy M
    Clin Pharmacol Ther; 1995 Aug; 58(2):198-209. PubMed ID: 7648770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impairment of the metabolism of dipyrone in asymptomatic carriers of the hepatitis B virus.
    Levy M; Leibowich I; Zylber-Katz E; Ilan Y; Granit L; Sviri S; Caraco Y
    Clin Pharmacol Ther; 1997 Jul; 62(1):6-14. PubMed ID: 9246014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity of saliva samples for the estimation of dipyrone metabolites pharmacokinetics.
    Caraco Y; Zylber-Katz E; Granit L; Levy M
    Arzneimittelforschung; 1993 Nov; 43(11):1204-8. PubMed ID: 8292065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formation and excretion of dipyrone metabolites in man.
    Zylber-Katz E; Granit L; Levy M
    Eur J Clin Pharmacol; 1992; 42(2):187-91. PubMed ID: 1618251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impairment of the metabolism of dipyrone in asymptomatic carriers of the hepatitis-B virus does not occur in rapid acetylators.
    Levy M; Safadi R; Zylber-Katz E; Granit L; Caraco Y
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):461-5. PubMed ID: 11699610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma kinetics of dipyrone metabolites in rapid and slow acetylators.
    Levy M; Flusser D; Zylber-Katz E; Granit L
    Eur J Clin Pharmacol; 1984; 27(4):453-8. PubMed ID: 6519153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of age and liver disease on the disposition and elimination of diazepam in adult man.
    Klotz U; Avant GR; Hoyumpa A; Schenker S; Wilkinson GR
    J Clin Invest; 1975 Feb; 55(2):347-59. PubMed ID: 1127104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of dipyrone and its metabolites.
    Levy M; Zylber-Katz E; Rosenkranz B
    Clin Pharmacokinet; 1995 Mar; 28(3):216-34. PubMed ID: 7758252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid and plasma concentrations of dipyrone metabolites after a single oral dose of dipyrone.
    Cohen O; Zylber-Katz E; Caraco Y; Granit L; Levy M
    Eur J Clin Pharmacol; 1998 Sep; 54(7):549-53. PubMed ID: 9832297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
    Chalon SA; Desager JP; Desante KA; Frye RF; Witcher J; Long AJ; Sauer JM; Golnez JL; Smith BP; Thomasson HR; Horsmans Y
    Clin Pharmacol Ther; 2003 Mar; 73(3):178-91. PubMed ID: 12621383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous determination of the main metabolites of dipyrone by high-pressure liquid chromatography.
    Damm D
    Arzneimittelforschung; 1989 Nov; 39(11):1415-7. PubMed ID: 2619775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
    Orlando R; Padrini R; Perazzi M; De Martin S; Piccoli P; Palatini P
    Clin Pharmacol Ther; 2006 May; 79(5):489-99. PubMed ID: 16678550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminopyrine metabolism in man: the acetylation of aminoantipyrine cosegregates with acetylation of caffeine.
    Agúndez JA; Carrillo JA; Martínez C; Benítez J
    Ther Drug Monit; 1995 Feb; 17(1):1-5. PubMed ID: 7725368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of rifampin administration on the disposition of fexofenadine.
    Hamman MA; Bruce MA; Haehner-Daniels BD; Hall SD
    Clin Pharmacol Ther; 2001 Mar; 69(3):114-21. PubMed ID: 11240975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of liver disease on the disposition of the opioid antagonist nalmefene.
    Frye RF; Matzke GR; Schade R; Dixon R; Rabinovitz M
    Clin Pharmacol Ther; 1997 Jan; 61(1):15-23. PubMed ID: 9024170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis.
    Shangraw RE; Fisher DM
    Clin Pharmacol Ther; 1999 Oct; 66(4):380-90. PubMed ID: 10546922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single and repeated dose pharmacokinetics of dexketoprofen trometamol in young and elderly subjects.
    Valles J; Artigas R; Bertolotti M; Crea A; Muller F; Paredes I; Capriati A
    Methods Find Exp Clin Pharmacol; 2006 Jun; 28 Suppl A():13-9. PubMed ID: 16801988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites.
    Tanaka E; Ishikawa A; Yamamoto Y; Osada A; Tsuji K; Fukao K; Misawa S; Iwasaki Y
    Int J Clin Pharmacol Ther Toxicol; 1992 Sep; 30(9):336-41. PubMed ID: 1428297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic profiles of the active metamizole metabolites after four different routes of administration in healthy dogs.
    Giorgi M; Łebkowska-Wieruszewska B; Lisowski A; Owen H; Poapolathep A; Kim TW; De Vito V
    J Vet Pharmacol Ther; 2018 Jun; 41(3):428-436. PubMed ID: 29352476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of picumast dihydrochloride in patients with liver cirrhosis.
    Neugebauer G; Raedsch R; Stiehl A; Kaufmann B; Besenfelder E; Neubert P; Walter-Sack I
    Arzneimittelforschung; 1989 Oct; 39(10A):1343-7. PubMed ID: 2576360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.